Business Wire

CA-ATTACKIQ

20.4.2022 15:02:05 CEST | Business Wire | Press release

Share
AttackIQ Announces Integration with Vectra AI Threat Detection and Response Platform to Help Customers Optimize their Security Control Effectiveness

AttackIQ ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced a new integration with Vectra®, an AI-driven threat detection and response platform that enables joint customers to detect attacks that have bypassed existing security controls and ensure rapid response to the latest threats.

"In today's hyper-complex threat environment, organizations must think proactively and adopt advanced security capabilities to prevent successful attacks," said Carl Wright, Chief Commercial Officer at AttackIQ. "This integration will allow our customers to validate the efficacy of the Vectra AI platform by utilizing AttackIQ's PCAP replay and related network scenarios to find and fix coverage gaps throughout their security infrastructure before adversaries exploit them."

AttackIQ operates under the "assume breach" mindset, recognizing that it is not a question of if but when an intruder will break past an organization's perimeter defense. Leveraging automated breach and attack simulation technology and the MITRE ATT&CK framework, the AttackIQ Security Optimization Platform enables organizations to measure their security controls performance, identify misconfigurations or gaps in coverage, and focus resources on areas with the highest probability of risk exposure.

"It is exciting to see AttackIQ and Vectra joining forces to help customers enable a proactive, threat-informed defense," said Geert Busse, Head of Next-Gen Solutions Pre Sales EMEA, Westcon. "As key vendors in our Westcon Next Generation Solutions go-to-market strategy, these two organizations are the backbone of our technology pillar, focusing on defense against emerging threats by delivering automation, integration and efficiency that our industry needs to detect and stop the latest generation of Threat Actors."

The Vectra Platform uses security-led artificial intelligence (AI) to power threat detection and response to ensure speed, precision, and efficiency in surfacing and stopping attacks before devastating impact. The platform captures data from network packets and logs that give insight into companies' public cloud and SaaS environment, federated identity, and data center networks. Vectra's patented approach to applying AI to detection analyzes all detection to prioritize threats and map events to MITRE ATT&CK framework without noise and hunting. It further drives appropriate remediation and rapid response through other tools already implemented in your security stack.

The AttackIQ Security Optimization Platform integration with the Vectra Threat Detection and Response Platform is available today.

To learn more about this integration and see it in action register for the May 5th demo here: https://attackiq.com/get-a-demo/weekly-demo/ .

About AttackIQ

AttackIQ, the leading independent vendor of breach and attack simulation solutions, built the industry's first Security Optimization Platform for continuous security control validation and improving security program effectiveness and efficiency. AttackIQ is trusted by leading organizations worldwide to plan security improvements and verify that cyberdefenses work as expected, aligned with the MITRE ATT&CK framework. The Company is committed to giving back to the cybersecurity community through its free award-winning AttackIQ Academy , open Preactive Security Exchange, and partnership with MITRE Engenuity's Center for Threat-Informed Defense . For more information, visit www.attackiq.com . Follow AttackIQ on Twitter , Facebook , LinkedIn , and YouTube .

About Vectra AI

Vectra® is a leader in threat detection and response for hybrid and multi-cloud enterprises. The Vectra platform uses AI to detect threats at speed across public cloud, identity, SaaS applications, and data centers. Only Vectra optimizes AI to detect attacker methods—the TTPs at the heart of all attacks—rather than simplistically alerting on "different". The resulting high-fidelity threat signal and clear context enables security teams to respond to threats sooner and to stop attacks in progress faster. Organizations worldwide rely on Vectra for cybersecurity resilience in the face of dangerous cyber threats and to prevent ransomware, supply chain compromise, identity takeovers, and other cyberattacks from impacting their businesses. For more information, visit vectra.ai.

Link:

ClickThru

Social Media:

https://www.facebook.com/AttackIQ/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com

Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release

Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that

2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release

CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen

Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release

A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye